Photo from wikipedia
1 Kopf AW, Morrill SD, Silberberg I. Broad spectrum of leukoderma acquisitum centrifugum. Arch Dermatol 1965; 92: 14–33; discussion 33–5. 2 Yang Y, Li S, Zhu G et al. A… Click to show full abstract
1 Kopf AW, Morrill SD, Silberberg I. Broad spectrum of leukoderma acquisitum centrifugum. Arch Dermatol 1965; 92: 14–33; discussion 33–5. 2 Yang Y, Li S, Zhu G et al. A similar local immune and oxidative stress phenotype in vitiligo and halo nevus. J Dermatol Sci 2017; 87: 50–9. 3 Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol 2017; 76: 745–53.e19. 4 Rothstein B, Joshipura D, Saraiya A et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 2017; 76: 1054–60.e1. 5 Liu LY, Strassner JP, Refat MA et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol 2017; 77: 675–82.e1.
Journal Title: Clinical and Experimental Dermatology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!